IP Library Granted Patent US 6,905,823
Granted Patent B2
US 6,905,823 · App. 09/971,742 · Granted Jun 14, 2005

Cellular arrays and methods of detecting and using genetic disorder markers

Assignee: Abbott Laboratories
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,905,823
App. No.
09/971,742
Granted
Jun 14, 2005
Kind
B2
Abstract

A method is disclosed for rapid molecular profiling of tissue or other cellular specimens by placing a donor specimen in an assigned location in a recipient array, providing copies of the array, and performing a different biological analysis of each copy. The results of the different biological analyses are compared to determine if there are correlations between the results of the different biological analyses at each assigned location. In some embodiments, the specimens may be tissue specimens from different tumors, which are subjected to multiple parallel molecular (including genetic and immunological) analyses. The results of the parallel analyses are then used to detect common molecular characteristics of the genetic disorder type, which can subsequently be used in the diagnosis or treatment of the disease. The biological characteristics of the tissue can be correlated with clinical or other information, to detect characteristics associated with the tissue, such as susceptibility or resistance to particular types of drug treatment. Other examples of suitable tissues which can be placed in the matrix include tissue from transgenic or model organisms, or cellular suspensions (such as cytological preparations or specimens of liquid malignancies or cell lines).

Claims (4)

1. A method of detecting the presence of cancerous cells in a specimen, the method comprising determining whether platelet derived growth factor beta (PDGFB) is amplified in the specimen, amplification indicating the presence of cancerous cells in the specimen.

2. The method of claim 1 , wherein the specimen is selected from the group consisting of lung, bladder, and endometrial tissues.

3. The method of claim 1 , wherein polymerase chain reaction (PCR) is performed to determine whether PDGFB is amplified in the specimen.

4. The method of claim 1 , wherein fluorescence in situ hybridization (FISH) is performed to determine whether PDGFB is amplified in the specimen.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2016
From: MULLER, UWE R.
To: VYSIS, INC.
Reel/Frame 037417/0780 →
CHANGE OF NAME Recorded Jan 6, 2016
From: VYSIS, INC.
To: ABBOTT MOLECULAR INC.
Reel/Frame 037447/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2006
From: KONONEN, JUHA
To: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 017468/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2006
From: KALLIONIEMI, OLLI P
To: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 017303/0674 →
Continuity (4)
Continuation 0942944800 · Oct 28, 1999
Provisional Application 6015049300 · Aug 24, 1999
Provisional Application 6010603800 · Oct 28, 1998
Related Publication 20020132246A1 · Sep 19, 2002